Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 1/2015

01-01-2015 | Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Inflammation and Hypertension: New Understandings and Potential Therapeutic Targets

Authors: Carmen De Miguel, Nathan P. Rudemiller, Justine M. Abais, David L. Mattson

Published in: Current Hypertension Reports | Issue 1/2015

Login to get access

Abstract

Research studying the role of inflammation in hypertension and cardiovascular disease has flourished in recent years; however, the exact mechanisms by which the activated immune cells lead to the development and maintenance of hypertension remain to be elucidated. The objectives of this brief review are to summarize and discuss the most recent findings in the field, with special emphasis on potential therapeutics to treat or prevent hypertension. This review will cover novel immune cell subtypes recently associated to the disease including the novel role of cytokines, toll-like receptors, and inflammasomes in hypertension.
Literature
1.
Schiffrin EL. Immune mechanisms in hypertension and vascular injury. Clin Sci. 2014;126:267–74.PubMed
2.
Bernardo R-IB. Renal infiltration of immunocompetent cells: cause and effect of sodium-sensitive hypertension. Clin Exp Nephrol. 2010;14:105–11.
3.
Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132–40.PubMedCentralPubMed
4.
Mattson DL. Infiltrating immune cells in the kidney in salt-sensitive hypertension and renal injury. Am J Physiol. 2014; (in press).
5.
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–6.PubMed
6.
Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol. 2010;11:7–13.PubMed
7.
Gol-Ara M, Jadidi-Niaragh F, Sadria R, Azizi G, Mirshafiey A. The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis. Arthritis. 2012;2012:805875.PubMedCentralPubMed
8.
Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21:1105–11.PubMed
9.
Ivanov I, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgamma t directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121–33.PubMed
10.
Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009;123:1004–11.PubMed
11.
Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55:500–7.PubMedCentralPubMed
12.
Wu J, Thabet SR, Kirabo A, Trott DW, Saleh MA, Xiao L, et al. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res. 2008;114:616–25.
13.••
Nguyen H, Chiasson VL, Chatterjee P, Kopriva SE, Young KJ, Mitchell BM. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res. 2013;97:696–704. This study demonstrates that IL-17 leads to the deleterious effects on the vasculature by promoting NOS3 phosphorylation and therefore decreasing enzyme activity.PubMedCentralPubMed
14.
Amador CA, Barrientos V, Peña J, Herrada AA, González M, Valdés S, et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension. 2014;63:797–803.PubMed
15.
Cornelius DC, Hogg JP, Scott J, Wallace K, Herse F, Moseley J, et al. Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy. Hypertension. 2013;62:1068–73.PubMedCentralPubMed
16.
Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469–76.PubMed
17.
Matrougui K, Zakaria AE, Kassan M, Choi S, Nair D, Gonzalez-Villalobos RA, et al. Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am J Pathol. 2011;178:434–41.PubMedCentralPubMed
18.
Kassan M, Galan M, Partyka M, Trebak M, Matrougui K. Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol. 2011;31:2534–42.PubMedCentralPubMed
19.
20.
Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus. 2004;13:635–8.PubMed
21.
Tipton AJ, Baban B, Sullivan JC. Female spontaneously hypertensive rats have greater renal anti-inflammatory T lymphocyte infiltration than males. Am J Physiol Regul Integr Comp Physiol. 2012;303:R359–67.PubMedCentralPubMed
22.•
Tipton AJ, Baban B, Sullivan JC. Female spontaneously hypertensive rats have a compensatory increase in renal regulatory T cells in response to elevations in blood pressure. Hypertension. 2014;64:557–64. With increasing emphasis on the use of female disease models, this group explores some of the inflammatory characteristics that may explain disparities in the presentation of hypertension between males and females.PubMed
23.
Kanellakis P, Dinh TN, Agrotis A, Bobik A. CD4(+)CD25(+)Foxp3(+) regulatory T cells suppress cardiac fibrosis in the hypertensive heart. J Hypertens. 2011;29:1820–8.PubMed
24.••
Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature. 2013;496:518–22. In vitro elevation of NaCl concentration can affect T cell differentiation. These findings could have major implications regarding the emerging hypothesis of sodium storage in the skin.PubMedCentralPubMed
25.
26.
Christ A, Temmerman L, Legein B, Daemen MJAP, Biessen EAL. Dendritic cells in cardiovascular diseases: epiphenomenon, contributor or therapeutic opportunity. Circulation. 2013;128:2603–13.PubMed
27.
Bobryshev YV, Lord RS. Ultrastructural recognition of cells with dendritic cell morphology in human aortic intima. Contacting interactions of vascular dendritic cells in athero-resistant and athero-prone areas of the normal aorta. Arch Histol Cytol. 1995;58:307–22.PubMed
28.
Soos TJ, Sims TN, Barisoni L, Lin K, Littman DR, Dustin ML, et al. CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int. 2006;70:591–6.PubMed
29.
D’Agostino PM, Gottfried-Blackmore A, Anandasabapathy N, Bulloch K. Brain dendritic cells: biology and pathology. Acta Neuropathol. 2012;124:599–614.PubMedCentralPubMed
30.
Van Vré EA, Van Brussel I, de Beeck KO, Hoymans VY, Vrints CJ, Bult H, et al. Changes in blood dendritic cell counts in relation to type of coronary artery disease and branchial endothelial cell function. Coron Artery Dis. 2010;21:87–96.PubMed
31.
Kretzschmar D, Betge S, Windisch A, Pistulli R, Rohm I, Fritzenwanger M, et al. Recruitment of circulating dendritic cell precursors into the infarcted myocardium and pro-inflammatory response in acute myocardial infarction. Clin Sci. 2012;123:387–98.PubMed
32.
Paul K, Kretzschmar D, Yilmaz A, Bärthlein B, Titze S, Wolf G, et al. Circulating dendritic cell precursors in chronic kidney disease: a cross-sectional study. BMC Nephrol. 2013;14:274.PubMedCentralPubMed
33.••
Kirabo A, Fontana V, Davies S, Roberts LJ, de Faria A, Galindo C, et al. Dendritic cell superoxide and isoketals activate T cells and promote angiotensin II hypertension. FASEB J. 2014;28:s1153.2. This study shows that AngII-induced hypertension is associated to isoketal formation and that isoketals scavengers can effectively decreased immunogenicity of DCs and attenuate hypertension.
34.
Nahmod K, Gentillini C, Vermeulen M, Uharek L, Wang Y, Zhang J, et al. Impaired function of dendritic cells deficient in angiotensin II type 1 receptors. J Pharmacol Exp Ther. 2010;334:854–62.PubMed
35.
Herrada AA, Contreras FJ, Marini NP, Amador CA, González PA, Cortés CM, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol. 2010;184:191–202.PubMed
36.
Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, et al. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation. 2010;122:2529–37.PubMedCentralPubMed
37.
Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28− and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134:17–32.PubMedCentralPubMed
38.••
Youn J-C, Yu HT, Lim BJ, Koh MJ, Lee J, Chang D-Y, et al. Immunosensescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013;62:126–33. This is the first study that directly demonstrates the involvement of T cells, specifically immunosenescent CD8+ cells, in human hypertension.PubMed
39.
Ramseyer VD, Garvin JL. Tumor necrosis factor α: regulation of renal function and blood pressure. Am J Physiol Renal Physiol. 2013;304:F1231.PubMedCentralPubMed
40.
Saulnier P-J, Gand E, Ducrocq G, Halimi J-M, Hulin-Delmotte C, Llaty P, et al. Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE cohort. Diabetes Care. 2014;37:1425–31.PubMed
41.
Chen CCA, Pedraza PL, Hao S, Stier CT, Ferreri NR. TNFR1-deficient mice display altered blood pressure and renal responses to AngII infusion. Am J Physiol Ren Physiol. 2010;299:F1141–50.
42.
Lucas R, Juillard P, Decoster E, Redard M, Burger D, Donati Y, et al. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol. 1997;27:1719–25.PubMed
43.
Min W, Wan T, Luo Y. Dissecting TNF-TNFR1/TNFR2 signaling pathways in vasculature. In: Dauphinee S, Karsan A, editors. Endothelial Dysfunction and Inflammation. 2010. pp:137–159.
44.
Onishi RM, Gaffen SL. Interleukin-17 and its targets genes: mechanisms of interleukin-17 function in disease. Immunology. 2010;129:311–21.PubMedCentralPubMed
45.
Wong CK, Lit LC, Tam LS, Li EK, Wong PT, Lam CW. Hyperproduction of IL-23 and Il-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008;127:385–93.PubMed
46.••
Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, et al. Induction of pathogenic Th17 cells by inducible salt-sensing SGK1. Nature. 2013;496:513–7. This paper demonstrates the importance of SGK1 expression for the polarization of naïve T cells into the Th17 phenotype, in presence of high salt.PubMedCentralPubMed
47.
Funakoshi Y, Ichiki T, Shimokawa H, Egashira K, Takeda K, Kaibuchi K, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension. 2001;38:100–4.PubMed
48.
Ishizawa K, Yoshizumi M, Tsuchiya K, Houchi H, Minakuchi K, Izawa Y, et al. Dual effects of endothelin-1 (1-31): induction of mesangial cell migration and facilitation of monocyte recruitment through monocyte chemoattractant protein-1 production by mesangial cells. Hypertens Res. 2004;27:433–40.PubMed
49.
Fliser D, Buchholz K, Haller H, for the EUTOPIA investigators. Antiinflammatory effects of angiotensin subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004;110:1103–7.PubMed
50.
Shen JZ, Morgan J, Tesch GH, Young MJ. CCL2-dependent macrophage recruitment is critical for mineralocorticoid receptor-mediated cardiac fibrosis, inflammation, and blood pressure responses in male mice. Endocrinology. 2014;155:1057–66.PubMed
51.
Chan CT, Moore JP, Budzyn K, Guida E, Diep H, Vinh A, et al. Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in DOCA salt-treated mice. Hypertension. 2012;60:1207–12.PubMed
52.
Brands MW, Banes-Berceli AKL, Inscho EW, Al-Azawi H, Allen AJ, Labazi H. Interleukin-6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and JAK2/STAT3 activation. Hypertension. 2010;56:879–84.PubMedCentralPubMed
53.•
Chamarthi B, Williams GH, Ricchiuti V, Srikumar N, Hopkins PN, Luther JM, et al. Inflammation and hypertension: the interplay of interleukin-6, dietary sodium and the renin-angiotensin system in humans. Am J Hypertens. 2011;24:1143–8. This study confirms the involvement of IL-6 in the AngII pathway in human hypertensives.PubMed
54.
Furuya Y, Satoh T, Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheum. 2010; 2010 Article ID 720305.
55.
Santilli F, Basili S, Ferrori P, Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med. 2007;2:256–68.PubMed
56.
Ruef J, Browatzki M, Pfeiffer CA, Schmidt J, Kranzhofer R. Angiotensin II promotes the inflammatory response to CD40 ligation via TRAF-2. Vasc Med. 2007;12:23–7.PubMed
57.•
Hausding M, Jurk K, Daub S, Kröller-Schön S, Stein J, Schwenk M, et al. CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction. Basic Res Cardiol. 2013;108:386. This paper demonstrates that genetic deletion of CD40L improves endothelial dysfunction and decreases aortic inflammation and oxidative stress.PubMed
58.
Derosa G, D’Angelo A, Mudellini A, Pesce RM, Fogari E, Maffioli P. Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. Curr Med Res Opin. 2012;28:1435–45.PubMed
59.
Surgit O, Erturk M, Akgul O, Pusuroglu H, Korkmaz AF, Isiksacan N, et al. Assessment of mean platelet volume and soluble CD40 ligand levels in patients with non-dipper hypertension, dippers and normotensives. Clin Exp Hypertens. 2014;27:1–5.
60.
Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–20.PubMed
61.
Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1–5.PubMed
62.•
McCarthy CG, Goulopoulou S, Wenceslau CF, Spitler K, Matsumoto T, Webb RC. Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol. 2014;306:H184–96. Nice review paper on the role of toll-like receptors in hypertension.PubMedCentralPubMed
63.
Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38:209–23.PubMed
64.
65.
Lin M, Tang SCW. Toll-like receptors: sensing and reacting to diabetic injury in the kidney. Nephrol Dial Transplant. 2014;29:746–54.PubMed
66.
Bauer EM, Shapiro R, Zheng Z, Ahmad F, Ishizawar D, Comhair SA, et al. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of toll-like receptor 4. Mol Med. 2012;18:1509–18.PubMedCentral
67.
Facholi Bomfim G, Szasz T, Carvalho MH, Webb RC. The Toll way to hypertension: role of the innate immune response. Endocrinol Metabol Syndr. 2011;S8:002.
68.
Iversen A-C. Inflammatory mechanisms in preeclampsia. Pregnancy Hyper. 2013;32:58.
69.
Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;108:1133–45.PubMedCentralPubMed
70.
Kawai T, Akira S. The role of pattern recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373–84.PubMed
71.
Mallard C. Innate immune regulation by toll-like receptors in the brain. ISRN Neurol. 2012; 2012 Article ID 701950.
72.
Jin B, Sun T, Yu XH, Yeo AE. The effects of TLR activation on T-cell development and differentiation. Clin Dev Immunol. 2012;2012:836485.PubMedCentralPubMed
73.
Xie F, von Dadelszen P, Nadeau J. CMV infection, TLR-2 and -4 expression, and cytokine profiles in early-onset preeclampsia with HELLP syndrome. Am J Reprod Immunol. 2014;71:379–86.PubMed
74.
Chatterjee P, Weaver LE, Doersch KM, Kopriva SE, Chiasson VL, Allen SJ, et al. Placental Toll-like receptor 3 and Toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice. PLoS One. 2012;7:e41884.PubMedCentralPubMed
75.
Goulopoulou S, Matsumoto T, Bomfim GF, Webb RC. Toll-like receptor 9 activation: a novel mechanism linking placenta-derived mitochondrial DNA and vascular dysfunction in preeclampsia. Clin Sci. 2012;123:429–35.PubMedCentralPubMed
76.
Thompson JA, Webb RC. The potential role of Toll-like receptors in programming of vascular dysfunction. Clin Sci. 2013;125:19–25.PubMedCentralPubMed
77.
Hardigan T, Sepulveda MA, Pedrosa NK, Webb RC. Toll-like receptor 2 blockade decreases contractility in angiotensin II-induced hypertensive rat resistance arteries. Hypertension. 2013;62:A189.
78.
Plavia V, Pyle C, Mezzetti E, Chen X, Didion S. Toll-like receptor 4 contributes to hypertension and endothelial dysfunction produced by angiotensin II. FASEB J. 2012;26:879.5.
79.
Liang C-F, Liu JTC, Wang Y, Xu A, Vanhoutte PM. Toll-like receptor 4 mutation protects obese mice against endothelial dysfunction by decreasing NADPH oxidase isoforms 1 and 4. Arterioscler Thromb Vasc Biol. 2013;33:777–84.PubMed
80.
Sollinger D, Eiβler R, Lorenz S, Strand S, Chmielewski S, Aoqui C, et al. Damage-associated molecular pattern activated toll-like receptor 4 signalling modulates blood pressure in L-NAME-induced hypertension. Cardiovasc Res. 2014;101:464–72.PubMed
81.
Speer T, Rohner L, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor 2. Immunity. 2013;38:754–68.PubMed
82.
Wu H, Chen G, Wyburn KR. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest. 2007;117:2847–59.PubMedCentralPubMed
83.
Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, et al. TLR recognition of self-nucleic acids hampers glucocorticoid activity in lupus. Nature. 2010;465:937–41.PubMedCentralPubMed
84.
Spirig R, Tsui J, Shaw S. The emerging role of TLR and innate immunity in cardiovascular disease. Cardiol Res Pract. 2012; 2012, Article ID 181394.
85.
Arslan F, Keogh B, McGuirk P, Parker AE. TLR2 and TLR4 in ischemia reperfusion injury. Mediat Inflamm. 2010;2010:704202.
86.
Arslan F, Houtgraaf JH, Keogh B, Kazemi K, de Jong R, McCormack WJ, et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012;5:279–87.PubMed
87.
Wang X, Lv X, Wang J, Yan H, Wang Z, Liu H, et al. Blocking TLR2 activity diminishes and stabilizes advanced atherosclerotic lesions in apolipoprotein E-deficient mice. Acta Pharmacol Sin. 2013;34:1025–35.PubMedCentralPubMed
88.
Lu Z, Zhang X, Li Y, Jin J, Huang Y. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice. J Endocrinol. 2013;216:61–71.PubMed
89.
Lin M, Yiu WH, Li RX, Wu HJ, Wong DWL, Chan LYY, et al. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int. 2013;83:887–900.PubMed
90.
Nunes KP, Bonfim GF, Szasz T, Carvalho MH, Webb RC. Treatment with anti-TLR4 antibody lowers blood pressure and improves erectile function in DOCA-salt rats. Hypertension. 2012;60:A254.
91.
Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC, et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci. 2012;122:535–43.PubMedCentralPubMed
92.
Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet. 2006;38:240–4.PubMed
93.
Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-Maitre B, et al. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell. 2007;25:713–24.PubMed
94.
Miao EA, Mao DP, Yudkovsky N, Bonneau R, Lorang CG, Warren SE, et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci U S A. 2010;107:3076–80.PubMedCentralPubMed
95.
Zhao Y, Yang J, Shi J, Gong YN, Lu Q, Xu H, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature. 2011;477:596–600.PubMed
96.
Roberts TL, Idris A, Dunn JA, Kelly GM, Burnton CM, Hodgson S, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science. 2009;323:1057–60.PubMed
97.
Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol. 2005;26:447–54.PubMed
98.
Sutterwala FS, Ogura Y, Flavell RA. The inflammasome in pathogen recognition and inflammation. J Leukoc Biol. 2007;82:259–64.PubMed
99.••
Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21:1732–44. Aside from demonstrating that NLRP3-deficient mice were protected from chronic kidney disease associated from unilateral ureteral obstruction, this study also examined a panel of human non-diabetic kidney diseases and found that NLRP3 mRNA increased with disease prevalence and correlated with impaired renal function.PubMedCentralPubMed
100.••
Andersen K, Eltrich N, Lichtnekert J, Anders HJ, Vielhauer V. The NLRP3/ASC inflammasome promotes T-cell-dependent immune complex glomerulonephritis by canonical and noncanonical mechanisms. Kidney Int. 2014. This study importantly demonstrated that NLRP3 inflammasome inhibition prevents T cell activation and infiltration into the kidney.
101.
Yang SM, Ka SM, Hua KF, Wu TH, Chuang YP, Lin YW, et al. Antroquinonol mitigates an accelerated and progressive IgA nephropathy model in mice by activating the Nrf2 pathway and inhibiting T cells and NLRP3 inflammasome. Free Radic Biol Med. 2013;61:285–97.PubMed
102.
Zhang C, Boini KM, Xia M, Abais JM, Li X, Liu Q, et al. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia. Hypertension. 2012;60:154–62.PubMedCentralPubMed
103.
Kim HJ, Lee DW, Ravichandran K, O Keys D, Akcay A, Nguyen Q, et al. NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J Pharmacol Exp Ther. 2013;346:465–72.PubMedCentralPubMed
104.
Wang Q, So A, Nussberger J, Tschopp J, Burnier M. Impact of NLRP3 inflammasome on the development of hypertension and renal and cardiac hypertrophy in 2K1C and DOCA/salt mice. Kidney Res Clin Pract. 2012;31(2):A83.
105.
Xia M, Xiong J, Boini KM, Abais JM, Li PL. Characteristics and hypertensive actions of renal medullary NALP3 inflammasomes in mice. FASEB J. 2012;26:879.884.
106.••
Omi T, Kumada M, Kamesaki T, Okuda H, Munkhtulga L, Yanagisawa Y, et al. An intronic variable number of tandem repeat polymorphisms of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene modifies gene expression and is associated with essential hypertension. Eur J Hum Genet. 2006;14:1295–305. This was the first genetic study to associate the CIAS1 (NLRP3) gene to essential hypertension susceptibility.PubMed
107.
Ruiz-Opazo N, Lopez LV, Herrera VL. The dual AngII/AVP receptor gene N119S/C163R variant exhibits sodium-induced dysfunction and cosegregates with salt-sensitive hypertension in the Dahl salt-sensitive hypertensive rat model. Mol Med. 2002;8:24–32.PubMedCentralPubMed
108.
Shaik R, Kolliputi N, Waxman AB. Activation of inflammasome in pulmonary arterial hypertension. Pulmonary hypertension: biomarkers, genetics, and genomics: insights into pathogenesis, A4865, 2010.
109.
Villegas LR, Kluck D, Field C, Oberley-Deegan RE, Woods C, Yeager ME, et al. Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome. Antioxid Redox Signal. 2013;18:1753–64.PubMedCentralPubMed
Metadata
Title
Inflammation and Hypertension: New Understandings and Potential Therapeutic Targets
Authors
Carmen De Miguel
Nathan P. Rudemiller
Justine M. Abais
David L. Mattson
Publication date
01-01-2015
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 1/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-014-0507-z

Other articles of this Issue 1/2015

Current Hypertension Reports 1/2015 Go to the issue

Pediatric Hypertension (B Falkner, Section Editor)

Cognitive Function in Hypertensive Children

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls

Antihypertensive Agents: Mechanisms of Drug Action (M Ernst, Section Editor)

Preventing the Progression of Prehypertension to Hypertension: Role of Antihypertensives

Hypertension and Obesity (E Reisin, Section Editor)

Hypertension and Insulin Resistance: Implications of Mitochondrial Dysfunction

Pediatric Hypertension (B Falkner, Section Editor)

Familial Aggregation and Childhood Blood Pressure

Pediatric Hypertension (B Falkner, Section Editor)

Treatment of Hypertension in Children with Chronic Kidney Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits